KINE SCIENCES

About KINE SCIENCES

Kine Sciences is a clinical-stage biopharmaceutical company headquartered in Seoul, South Korea, focused on developing treatments for a variety of critical diseases. The company was originally founded as Bio Pep Co., Ltd. in August 2016, later changing its name to Kine Sciences Co.,Ltd in March 2019. The current co-CEOs, Hee Kyung Kim and Dae Ho Cho, who is also the Founder and CTO, were inaugurated in March 2022.

The company's core business revolves around the research and development of innovative medicines using ultra-small peptides derived from a novel cytokine, ERDR1, which the company first identified. This approach targets chronic immune diseases, neurological disorders, and cancer. Kine Sciences' business model is centered on advancing its drug candidates through the clinical trial pipeline with the ultimate goal of securing regulatory approval and commercializing these therapies. The company's operations are financed through a series of funding rounds, including a Series A in 2018, Series B and B2 in 2019 and 2020, and a Series C in 2021, from investors such as Industrial Bank of Korea, Aion Asset Management, and HB Investment.

The main product pipeline includes several drug candidates at various stages of development. KINE-101 is being investigated for autoimmune disorders like Rheumatoid Arthritis (RA) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with the KINE-101A compound having received IND approval from the US FDA for a Phase 1 trial. Other pipeline candidates include KINE-201 for dermatological and respiratory conditions, KINE-301 for psoriasis, KINE-401 for solid tumors, and KINE-501 for central nervous system diseases like Alzheimer's. The company highlights the advantages of its ultra-small peptides, such as lower production costs, reduced immunogenicity, and the potential for oral administration, which distinguishes them from conventional treatments.